Mimotopes for tumor‐specific T lymphocytes in human cancer determined with combinatorial peptide libraries

Mimotopes of a tumor‐associated T cell epitope were determined using randomized and combinatorial peptide libraries and a CD8+ T cell clone specific for the cutaneous T cell lymphoma cell line MyLa. Antigen recognition by this clone was found to be HLA‐B8 restricted. More than 80 % of HLA‐matched patients with cutaneous T cell lymphoma had mimotope‐specific CD8+ T cells in their peripheral blood. Mimotope‐specific T cells isolated and expanded from a patient lysed MyLa cells in in vitro assays thus demonstrating their cytolytic capacity and tumor specificity. Mimotope vaccination of a patient without detectable mimotope‐specific T cells induced frequencies of these cells of up to 1.82 % of the peripheral blood CD8+ T cells.

[1]  Gnther Jung,et al.  Combinatorial Peptide and Nonpeptide Libraries , 1996 .

[2]  M. Greene,et al.  Mycosis fungoides: epidemiologic observations. , 1979, Cancer treatment reports.

[3]  P. Brossart,et al.  Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. , 1998, Cancer research.

[4]  T. Boon.  Toward a genetic analysis of tumor rejection antigens. , 1992, Advances in cancer research.

[5]  J. Renauld,et al.  Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. , 1997, Methods.

[6]  J. Johnston,et al.  Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes , 1996, The Journal of experimental medicine.

[7]  M. Brehm,et al.  A molecular basis for how a single TCR interfaces multiple ligands. , 1998, Journal of immunology.

[8]  K. Wiesmüller,et al.  Molecular basis for the recognition of two structurally different major histocompatibility complex/peptide complexes by a single T-cell receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Kienle,et al.  Determination of T cell epitopes with random peptide libraries. , 1996, Journal of immunological methods.

[10]  P. Bruggen,et al.  Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.

[11]  Hans-Georg Rammensee,et al.  MHC Ligands and Peptide Motifs , 1998, Molecular Biology Intelligence Unit.

[12]  G. A. Schellekens,et al.  The use of dedicated peptide libraries permits the discovery of high affinity binding peptides. , 1995, Journal of immunological methods.

[13]  S. Kienle,et al.  Specificity and degeneracy of minor histocompatibility antigen-specific MHC-restricted CTL. , 1996, Journal of immunology.

[14]  J. Drijfhout,et al.  The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  E. Jaffe,et al.  Report of the symposium on Cutaneous Lymphomas: Sixth International Conference on Malignant Lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  E. Jaffe,et al.  The Revised European‐American Classification of Lymphoid Neoplasms (REAL): a new perspective for the classification of cutaneous lymphomas , 1997, Journal of cutaneous pathology.

[17]  K. Wiesmüller,et al.  Elucidation of T-cell epitopes: a synthetic approach with random peptide libraries. , 1995, Biochemical Society transactions.

[18]  S. Kienle,et al.  Decrypting the structure of major histocompatibility complex class I- restricted cytotoxic T lymphocyte epitopes with complex peptide libraries , 1995, The Journal of experimental medicine.

[19]  A. McMichael,et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides , 1986, Cell.

[20]  P. Walden,et al.  T-cell epitope determination. , 1996, Current opinion in immunology.

[21]  H. Rammensee,et al.  Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.

[22]  J. Schneider-Mergener,et al.  T-cell epitope mapping by flow cytometry , 1998, Nature Medicine.

[23]  P. Coulie,et al.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells , 1992, International journal of cancer.

[24]  B. Longley,et al.  Tumor‐specific peptides in cutaneous T‐cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T‐cell receptor , 1998, International journal of cancer.

[25]  S. Ferrone,et al.  Cloning and in vitro expression of a melanoma-associated antigen immunogenic in patients with melanoma. , 1991, Journal of immunology.

[26]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[27]  S. Kienle,et al.  Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. , 1996, Journal of immunology.

[28]  P. Parham,et al.  The Bw4/Bw6 difference between HLA-B*0802 and HLA-B*0801 changes the peptides endogenously bound and the stimulation of alloreactive T cells , 1998, Immunogenetics.

[29]  B. Seliger,et al.  Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? , 1998, Cancer research.

[30]  R. Edelson.  Cutaneous T cell lymphoma: mycosis fungoides, Sézary syndrome, and other variants. , 1980, Journal of the American Academy of Dermatology.